Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure

References

• ColosiaADPalenciaRKhanSPrevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature reviewDiabetes Metab Syndr Obes2013632733824082791
   PubMedGoogle Scholar
• Centers for Disease Control and PreventionNational Diabetes Statistics Report, 2014AtlantaCDC2014
   Google Scholar
• PantaloneKMHobbsTMWellsBJClinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health systemBMJ Open Diabetes Res Care201531e000093
   PubMed Web of Science ®Google Scholar
• RapsomanikiETimmisAGeorgeJBlood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million peopleLancet201438399321899191124881994
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationCardiovascular disease and risk managementDiabetes Care201639Suppl 1S60S7126696684
   PubMedGoogle Scholar
• LorberDImportance of cardiovascular disease risk management in patients with type 2 diabetes mellitusDiabetes Metab Syndr Obes2014716918324920930
   PubMedGoogle Scholar
• LastraGSyedSKurukulasuriyaLRManriqueCSowersJRType 2 diabetes mellitus and hypertension: an updateEndocrinol Metab Clin North Am201443110312224582094
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ199831771607037139732337
   PubMed Web of Science ®Google Scholar
• AdlerAIStrattonIMNeilHAAssociation of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational studyBMJ2000321725841241910938049
   PubMed Web of Science ®Google Scholar
• EmdinCARahimiKNealBCallenderTPerkovicVPatelABlood pressure lowering in type 2 diabetes: a systematic review and meta-analysisJAMA2015313660361525668264
   PubMed Web of Science ®Google Scholar
• RydénLGrantPJAnkerSDESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEur Heart J201334393035308723996285
   PubMed Web of Science ®Google Scholar
• WeberMASchiffrinELWhiteWBClinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of HypertensionJ Clin Hypertens (Greenwich)2014161142624341872
   PubMed Web of Science ®Google Scholar
• GoASBaumanMAKingSMAn effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and PreventionHypertension201463487888524243703
   PubMed Web of Science ®Google Scholar
• JamesPAOparilSCarterBL2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)JAMA2014311550752024352797
   PubMed Web of Science ®Google Scholar
• ArguedasJALeivaVWrightJMBlood pressure targets for hypertension in people with diabetes mellitusCochrane Database Syst Rev201310CD00827724170669
   PubMed Web of Science ®Google Scholar
• HandelsmanYBloomgardenZTGrunbergerGAmerican Association of Clinical Endocrinologists and American College of Endocrinology: clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015Endocr Pract201521Suppl 1187
   PubMed Web of Science ®Google Scholar
• DaskalopoulouSSRabiDMZarnkeKBThe 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertensionCan J Cardiol201531554956825936483
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIConsensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm: 2016 executive summaryEndocr Pract20162218411326731084
   PubMed Web of Science ®Google Scholar
• RosendorffCBlood pressure targets in patients with diabetes: a new perspectiveJ Am Soc Hypertens20159533433625979409
   PubMed Web of Science ®Google Scholar
• XieXAtkinsELvJEffects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysisLancet20163871001743544326559744
   PubMed Web of Science ®Google Scholar
• CasagrandeSSFradkinJESaydahSHRustKFCowieCCThe prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010Diabetes Care20133682271227923418368
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMADeFronzoRAInhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitusEndocr Pract200814678279018996802
   PubMedGoogle Scholar
• DeFronzoRADavidsonJADel PratoSThe role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes Obes Metab201214151421955459
   PubMed Web of Science ®Google Scholar
• VallonVThe mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitusAnnu Rev Med20156625527025341005
   PubMed Web of Science ®Google Scholar
• HedigerMARhoadsDBMolecular physiology of sodium-glucose cotransportersPhysiol Rev199474499310267938229
   PubMed Web of Science ®Google Scholar
• WrightEMLooDDHirayamaBABiology of human sodium glucose transportersPhysiol Rev201191273379421527736
   PubMed Web of Science ®Google Scholar
• RahmouneHThompsonPWWardJMSmithCDHongGBrownJGlucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetesDiabetes200554123427343416306358
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMADefronzoRANortonLNovel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humansDiabetes201362103324332824065789
   PubMed Web of Science ®Google Scholar
• Invokana (canagliflozin) tablets, for oral use [prescribing information]Titusville, NJJanssen Pharmaceuticals, Inc2016
   Google Scholar
• Farxiga (dapagliflozin) tablets, for oral use [prescribing information]Wilmington, DEAstraZeneca Pharmaceuticals LP2016
   Google Scholar
• Jardiance (empagliflozin) tablets, for oral use [prescribing information]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2016
   Google Scholar
• YangXPLaiDZhongXYShenHPHuangYLEfficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysisEur J Clin Pharmacol201470101149115825124541
   PubMed Web of Science ®Google Scholar
• ZhangMZhangLWuBSongHAnZLiSDapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trialsDiabetes Metab Res Rev201430320422124115369
   PubMed Web of Science ®Google Scholar
• LiakosAKaragiannisTAthanasiadouEEfficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysisDiabetes Obes Metab2014161098499324766495
   PubMed Web of Science ®Google Scholar
• WhalenKMillerSOngeESThe role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetesClin Ther20153761150116625891804
   PubMed Web of Science ®Google Scholar
• FerranniniEMuscelliEFrascerraSMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsJ Clin Invest2014124249950824463454
   PubMed Web of Science ®Google Scholar
• MerovciASolis-HerreraCDanieleGDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose productionJ Clin Invest2014124250951424463448
   PubMed Web of Science ®Google Scholar
• MerovciAMariASolisCDapagliflozin lowers plasma glucose concentration and improves β-cell functionJ Clin Endocrinol Metab201510051927193225710563
   PubMed Web of Science ®Google Scholar
• CefaluWTLeiterLAYoonKHEfficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trialLancet2013382989694195023850055
   PubMed Web of Science ®Google Scholar
• BolinderJLjunggrenÖJohanssonLDapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metforminDiabetes Obes Metab201416215916923906445
   PubMed Web of Science ®Google Scholar
• RidderstråleMAndersenKRZellerCKimGWoerleHJBroedlUCComparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trialLancet Diabetes Endocrinol20142969170024948511
   PubMed Web of Science ®Google Scholar
• FerranniniGHachTCroweSSanghviAHallKDFerranniniEEnergy balance after sodium-glucose cotransporter 2 inhibitionDiabetes Care20153891730173526180105
   PubMed Web of Science ®Google Scholar
• OlivaRVBakrisGLBlood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitorsJ Am Soc Hypertens20148533033924631482
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood2015 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdfAccessed January 12, 2016
   Google Scholar
• US Food Drug AdministrationFDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections2015 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm475463.htmAccessed January 12, 2016
   Google Scholar
• PetersALBuschurEOBuseJBCohanPDinerJCHirschIBEuglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibitionDiabetes Care20153891687169326078479
   PubMed Web of Science ®Google Scholar
• RoachPSkierczynskiPEuglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozinDiabetes Care2016391e326519331
   PubMed Web of Science ®Google Scholar
• HineJPatersonHAbrolERussell-JonesDHerringRSGLT inhibition and euglycaemic diabetic ketoacidosisLancet Diabetes Endocrinol201537503504
   PubMed Web of Science ®Google Scholar
• EronduNDesaiMWaysKMeiningerGDiabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical programDiabetes Care20153891680168626203064
   PubMed Web of Science ®Google Scholar
• RosenstockJFerranniniEEuglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitorsDiabetes Care20153891638164226294774
   PubMed Web of Science ®Google Scholar
• BakerWLSmythLRRicheDMBourretEMChamberlinKWWhiteWBEffects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysisJ Am Soc Hypertens201484262275.e924602971
   PubMed Web of Science ®Google Scholar
• MajewskiCBakrisGLBlood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetesDiabetes Care201538342943025715414
   PubMed Web of Science ®Google Scholar
• ListJFWooVMoralesETangWFiedorekFTSodium-glucose cotrans-port inhibition with dapagliflozin in type 2 diabetesDiabetes Care200932465065719114612
   PubMed Web of Science ®Google Scholar
• LovshinJAGilbertREAre SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?Curr Hypertens Rep201517655125893475
   PubMed Web of Science ®Google Scholar
• Lambers HeerspinkHJde ZeeuwDWieLLeslieBListJDapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetesDiabetes Obes Metab201315985386223668478
   PubMed Web of Science ®Google Scholar
• AucottLRothnieHMcIntyreLThapaMWaweruCGrayDLong-term weight loss from lifestyle intervention benefits blood pressure? A systematic reviewHypertension200954475676219704106
   PubMed Web of Science ®Google Scholar
• SiebenhoferAJeitlerKBergholdALong-term effects of weight-reducing diets in hypertensive patientsCochrane Database Syst Rev20119CD00827421901719
   PubMed Web of Science ®Google Scholar
• SiebenhoferAJeitlerKHorvathKBergholdASieringUSemlitschTLong-term effects of weight-reducing drugs in hypertensive patientsCochrane Database Syst Rev20133CD00765423543553
   PubMed Web of Science ®Google Scholar
• Souto-GallardoMLGascónMBCruzAJEffect of weight loss on metabolic control in people with type 2 diabetes mellitus: systematic reviewNutr Hosp20112661242124922411367
   PubMed Web of Science ®Google Scholar
• CefaluWTStenlofKLeiterLAEffects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetesDiabetologia20155861183118725813214
   PubMed Web of Science ®Google Scholar
• VallonVRichterKBlantzRCThomsonSOsswaldHGlomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorptionJ Am Soc Nephrol199910122569257610589696
   PubMed Web of Science ®Google Scholar
• ThomsonSCVallonVBlantzRCKidney function in early diabetes: the tubular hypothesis of glomerular filtrationAm J Physiol Renal Physiol20042861F8F1514656757
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMADeFronzoRALowering plasma glucose concentration by inhibiting renal sodium-glucose cotransportJ Intern Med2014276435236324690096
   PubMed Web of Science ®Google Scholar
• ŠkrtićMCherneyDZSodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathyCurr Opin Nephrol Hypertens20152419610325470017
   PubMed Web of Science ®Google Scholar
• ChiltonRTikkanenICannonCPEffects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetesDiabetes Obes Metab201517121180119326343814
   PubMed Web of Science ®Google Scholar
• CherneyDZPerkinsBASoleymanlouNThe effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitusCardiovasc Diabetol2014132824475922
   PubMed Web of Science ®Google Scholar
• StenlöfKCefaluWTKimKAEfficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes Obes Metab201315437238223279307
   PubMed Web of Science ®Google Scholar
• FerranniniERamosSJSalsaliATangWListJFDapagliflozin mono-therapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trialDiabetes Care201033102217222420566676
   PubMed Web of Science ®Google Scholar
• RodenMWengJEilbrachtJEmpagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialLancet Diabetes Endocrinol20131320821924622369
   PubMed Web of Science ®Google Scholar
• Lavalle-GonzálezFJJanuszewiczADavidsonJEfficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia201356122582259224026211
   PubMed Web of Science ®Google Scholar
• BaileyCJGrossJLPietersABastienAListJFEffect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialLancet201037597332223223320609968
   PubMed Web of Science ®Google Scholar
• HäringHUMerkerLSeewaldt-BeckerEEmpagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care20143761650165924722494
   PubMed Web of Science ®Google Scholar
• WildingJPCharpentierGHollanderPEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trialInt J Clin Pract201367121267128224118688
   PubMed Web of Science ®Google Scholar
• MatthaeiSBoweringKRohwedderKGrohlAParikhSDapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trialDiabetes Care201538336537225592197
   PubMed Web of Science ®Google Scholar
• HäringHUMerkerLSeewaldt-BeckerEEmpagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trialDiabetes Care201336113396340423963895
   PubMed Web of Science ®Google Scholar
• ForstTGuthrieRGoldenbergREfficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazoneDiabetes Obes Metab201416546747724528605
   PubMed Web of Science ®Google Scholar
• RosenstockJVicoMWeiLSalsaliAListJFEffects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapyDiabetes Care20123571473147822446170
   PubMed Web of Science ®Google Scholar
• KovacsCSSeshiahVSwallowREmpagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trialDiabetes Obes Metab201416214715823906415
   PubMed Web of Science ®Google Scholar
• NealBPerkovicVde ZeeuwDEfficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesDiabetes Care201538340341125468945
   PubMed Web of Science ®Google Scholar
• WildingJPWooVSolerNGLong-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trialAnn Intern Med2012156640541522431673
   PubMed Web of Science ®Google Scholar
• RosenstockJJelaskaAZellerCKimGBroedlUCWoerleHJImpact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trialDiabetes Obes Metab2015171093694826040302
   PubMed Web of Science ®Google Scholar
• WeirMRJanuszewiczAGilbertREEffect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitusJ Clin Hypertens (Greenwich)2014161287588225329038
   PubMed Web of Science ®Google Scholar
• SjöströmCDJohanssonPPtaszynskaAListJJohnssonEDapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetesDiab Vasc Dis Res201512535235826008804
   PubMed Web of Science ®Google Scholar
• WeberMAMansfieldTACainVAIqbalNParikhSPtaszynskaABlood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 studyLancet Diabetes Endocrinol20164321122026620248
   PubMed Web of Science ®Google Scholar
• TikkanenINarkoKZellerCEmpagliflozin reduces blood pressure in patients with type 2 diabetes and hypertensionDiabetes Care201538342042825271206
   PubMed Web of Science ®Google Scholar
• TownsendRRMachinIRenJReductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertensionJ Clin Hypertens (Greenwich)2016181435226663712
   PubMed Web of Science ®Google Scholar
• O’BrienEParatiGStergiouGEuropean Society of Hypertension position paper on ambulatory blood pressure monitoringJ Hypertens20133191731176824029863
   PubMed Web of Science ®Google Scholar
• ManciaGFagardRNarkiewiczK2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J201334282159221923771844
   PubMed Web of Science ®Google Scholar
• FriedmanOLoganAGCan nocturnal hypertension predict cardiovascular risk?Integr Blood Press Control20092253721949613
   PubMedGoogle Scholar
• LopezJMBaileyRARupnowMFAnnunziataKCharacterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide surveyClin Ther201436449450624508418
   PubMed Web of Science ®Google Scholar
• GavinJR3rdDaviesMJDaviesMVijapurkarUAlbaMMeiningerGThe efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitusCurr Med Res Opin20153191693170226121561
   PubMed Web of Science ®Google Scholar
• FerdinandKCSemanLSalsaliADesign of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitusPoster presented at: American Association of Clinical Endocrinologists 25th Annual MeetingMay 25–29, 2016Orlando, FL
   Google Scholar
• Janssen Research & DevelopmentCanagliflozin cardiovascular assessment study (CANVAS) Available from: https://www.clinicaltrials.gov/ct2/show/NCT01032629. NLM identifier: NCT01032629Accessed January 8, 2016
   Google Scholar
• NealBPerkovicVde ZeeuwDRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS): a randomized placebo-controlled trialAm Heart J20131662217223.e1123895803
   PubMed Web of Science ®Google Scholar
• AstraZenecaMulticenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) Available from: https://clinicaltrials.gov/ct2/show/NCT01730534. NLM identifier: NCT01730534Accessed January 8, 2016
   Google Scholar
• TIMI Study GroupDECLARE-TIMI 58 Available from: http://www.timi.org/index.php?page=declare-timi-58Accessed April 13, 2016
   Google Scholar
• Merck Sharp & DohmeCardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus and established vascular disease: the VERTIS CV Study (MK-8835-004) Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT01986881. NLM identifier: NCT01986881Accessed January 8, 2016
   Google Scholar
• ZinmanBWannerCLachinJMEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetesN Engl J Med2015373222117212826378978
   PubMed Web of Science ®Google Scholar
• Abdul-GhaniMDel PratoSChiltonRDeFronzoRASGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME studyDiabetes Care201639571772527208375
   PubMed Web of Science ®Google Scholar
• DraznerMHThe progression of hypertensive heart diseaseCirculation2011123332733421263005
   PubMed Web of Science ®Google Scholar